2014’s Biotech IPO Class: Strong Starts
This article was originally published in Start Up
Executive Summary
Fifteen biotechs from the IPO class of 2014 have more than doubled their values since their debuts. Those stand-outs drove the impressive overall performance of the 67 newly public biotechs in the cohort: overall, the average IPO in 2014 was up 52.2% as of February 27.